EGFRAP encodes a new negative regulator of the EGFR acting in both normal and oncogenic EGFR/Ras-driven tissue morphogenesis.
Activation of Ras signaling occurs in ~30% of human cancers. However, activated Ras alone is insufficient to produce malignancy. Thus, it is imperative to identify those genes cooperating with activated Ras in driving tumoral growth. In this work, we have identified a novel EGFR inhibitor, which we...
Enregistré dans:
Auteurs principaux: | Jennifer Soler Beatty, Cristina Molnar, Carlos M Luque, Jose F de Celis, María D Martín-Bermudo |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/4e3c5c6576e54e079590b3e69a6c23d4 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth
par: Chiswili Chabu, et autres
Publié: (2017) -
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
par: Beth O. Van Emburgh, et autres
Publié: (2016) -
Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
par: Wen M, et autres
Publié: (2018) -
Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
par: Shang-Gin Wu, et autres
Publié: (2011) -
Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients
par: Masykura N, et autres
Publié: (2019)